Does Dr. PRASAD KANDULA have financial conflicts of interest?

Dr. PRASAD KANDULA (M.D.) has received a total of $10,018 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $10,018 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. PRASAD KANDULA?

According to CMS Open Payments data, Dr. PRASAD KANDULA received funding from MEDTRONIC ($1,320), AMGEN ($1,156), and NOVARTIS PHARMACEUTICALS CORPORATION ($864).

Does Dr. PRASAD KANDULA receive research grants or speaking fees?

Dr. PRASAD KANDULA has received $10,018 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. PRASAD KANDULA

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Interventional Cardiology

Practice Location: BELLEVILLE, IL 62226

NPI Number: 1164518460

LIFETIME INDUSTRY VALUE

$10,018

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. KANDULA is a verified Internal Medicine, Interventional Cardiology practitioner based in BELLEVILLE, IL.

Between 2021 and 2025, Dr. KANDULA had an overall industry promotional and research financial footprint of $10,018 as recorded in the federal CMS Open Payments database.

$10,018 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. KANDULA's primary funding source is MEDTRONIC, which accounts for $1,320 (representing 13.2% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

MEDTRONIC

Rank 1

$1,320

13.2%

AMGEN

Rank 2

$1,156

11.5%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 3

$864

8.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.